In recent years, as the prevalence of metabolic diseases continues to rise, global diabetes treatment has entered an era characterized by precision therapy and long-acting formulations. A number of innovative drugs have been launched, providing more individualized treatment options for patients with type 2 diabetes.
At the same time, professional pharmaceutical supply and export service providers—represented by DengyueMed, a Chinese innovative drug exporter—are actively helping bring China-developed diabetes therapies to broader international markets.
This article highlights five noteworthy new drugs to help healthcare professionals and industry stakeholders quickly grasp the latest developments.
1. Enoglutide Injection
Drug Class: GLP-1 receptor agonist
Indication: Glycemic control in type 2 diabetes
Mechanism of Action
Enoglutide activates GLP-1 receptors to stimulate insulin secretion and suppress glucagon release. It also delays gastric emptying and reduces appetite, enabling multi-target glucose control.
Clinical Highlights
● Long-acting dosing design improves adherence
● Potential benefits for weight management
● Relatively low risk of hypoglycemia
Summary: Enoglutide represents an important step forward in long-acting GLP-1 therapy.
2. Olorigliflozin Capsules
Drug Class: SGLT2 inhibitor
Indication: Adults with type 2 diabetes
Mechanism of Action
Olorigliflozin inhibits renal SGLT2 transporters, reducing glucose reabsorption and promoting urinary glucose excretion, thereby lowering blood glucose levels.
Clinical Advantages
● Independent of pancreatic β-cell function
● Supports weight and blood pressure management
● Potential cardiorenal benefits
Summary: Olorigliflozin provides a new oral option for comprehensive metabolic management.
3. Visepegenatide Injection
Drug Class: Novel GLP-1–based therapy
Indication: Type 2 diabetes
Key Features
Visepegenatide has been structurally optimized to:
● Extend in-vivo half-life
● Improve receptor selectivity
● Enhance gastrointestinal tolerability
Clinical Outlook
It shows particular appeal for patients who need stronger glycemic control while also focusing on weight management.
Summary: This drug reflects the GLP-1 trend toward “longer-acting and better tolerated” therapies.
4. Cofrogliptin Tablets
Drug Class: DPP-4 inhibitor
Indication: Monotherapy or combination therapy for type 2 diabetes
Mechanism and Value
Cofrogliptin inhibits the DPP-4 enzyme, prolonging endogenous GLP-1 activity, thereby:
● Enhancing glucose-dependent insulin secretion
● Reducing postprandial glucose
● Maintaining a low hypoglycemia risk
Clinical Positioning
Suitable for:
● Elderly patients
● Patients needing a mild oral glucose-lowering regimen
● Combination therapy settings
Summary: A safety- and tolerability-oriented, steady treatment option.
5. Sentagliptin Phosphate Tablets
Drug Class: Next-generation DPP-4 inhibitor
R&D Focus: High selectivity and extended duration
Key Advantages
● Higher DPP-4 selectivity
● Potential for longer duration of action
● Flexible combination therapy design
Market Significance
Amid intense competition in oral antidiabetic drugs, Sentagliptin strengthens the clinical position of the DPP-4 class through molecular optimization, offering a new oral option for patients requiring stable glycemic control.
Industry Trend: From “Glucose Lowering” to “Comprehensive Metabolic Management”
Overall, these five drugs reflect several clear trends:
● ✅ Long-acting therapies are becoming mainstream
● ✅ Weight and cardiorenal benefits are gaining attention
● ✅ Target refinement and molecular optimization continue
● ✅ Global expansion of Chinese innovative drugs is accelerating
In the future, diabetes treatment will move beyond simple glucose control toward personalized and comprehensive metabolic management.
Conclusion
The launch of Enoglutide, Olorigliflozin, Visepegenatide, Cofrogliptin, and Sentagliptin phosphate marks a new, more diversified and precise phase in diabetes care. As Chinese innovative drugs continue to expand globally, professional service providers such as DengyueMed are expected to play an increasingly important bridging role in the international pharmaceutical supply chain.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always follow professional medical guidance.
No comments:
Post a Comment